| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease of the pulmonary artery. We previously reported that the calcium-sensing receptor (CaSR) was upregulated in pulmonary arterial smooth muscle cells (PASMCs) from idiopathic pulmonary arterial hypertension (IPAH) patients. In this study, we examined involvement of platelet-derived growth factor (PDGF) on CaSR expression. The expression of PDGF receptors was stronger in IPAH-PASMCs than in normal-PASMCs.The PDGF-induced CaSR upregulation was attenuated by the siRNA knockdown of PDGF receptors.These results suggest that enhanced PDGF signaling is involved in the CaSR upregulation, leading excessive PASMC proliferation and vascular remodeling in IPAH patients. The linkage between CaSR and PDGF signals is a novel pathophysiological mechanism contributing to the development of PAH.
|
